Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
INDUCE-seq® has demonstrated the ability to map on-target and off-target DNA breaks with high precision in clinically relevant systems. The platform has been validated in peer-reviewed research for characterizing CRISPR-Cas9 specificity and supports rapid safety assessment for gene-editing therapies. The company’s Early Access Program allows partners to obtain actionable data within days, accelerating development timelines. No clinical results as the company does not develop its own therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Broken String Biosciences.